Skin Disorders News

ORLANDO, Fla. — Racial and ethnic minority children experienced disparities in health care utilization and school attendance related to their atopic dermatitis, according to late-breaking research presented at the American Academy of Dermatology Annual Meeting.

ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, Junko Takeshita, MD, PhD, discusses her late-breaking research presentation on racial and ethnic disparities in health care utilization and school attendance among children with atopic dermatitis.

The FDA has approved Dupixent injection to treat adults with moderate-to-severe atopic dermatitis whose disease in not adequately controlled with topical therapies or when those therapies are not advisable.

ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, Vicki Lawrence discusses her diagnosis of chronic idiopathic urticaria and the patient educational campaign that she represents.

ORLANDO, Fla. —In a video perspective from the American Academy of Dermatology Annual Meeting, Andrew Blauvelt, MD, MBA, discusses his late-breaking research presentation on Dupixent with concomitant topical corticosteroids to treat moderate-to-severe atopic dermatitis.

ATLANTA — The association between atopic disease and obesity among children and adolescents was significantly influenced by gender, according to research presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology.

ORLANDO, Fla. — Janus kinase inhibitors may be a promising treatment for atopic dermatitis, alopecia areata, and vitiligo, according to research being presented at the American Academy of Dermatology Annual Meeting.

There was a significant difference in thickness of the granular layer in patients with palmar psoriasis vs. those with hand eczema, according to study results recently published in the Journal of the American Academy of Dermatology.

The FDA announced it has approved Eucrisa ointment to treat mild-to-moderate atopic dermatitis in patients aged 2 years and older.

Regeneron Pharmaceuticals and Sanofi have announced in a press release that the European Medicines Agency has accepted to review the marketing authorization application for Dupixent for treating adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.